community. The data will be translated for practitioners and others engaged in parent training work. Data that are collected will be stored physically and electronically by the contractors collecting the respective data at their offices. De-identified electronic database(s) will be transferred to CDC. Any hard copies of data will be destroyed after the data has been successfully entered, cleaned, and backed up into the database. We anticipate that the surveys will take between 15 minutes to 45 minutes to complete (depending on which survey is being completed).

The proposed data collection fits into the National Center for Injury Prevention and Control Research Agenda Priorities in Preventing Child Maltreatment. Research is essential to ensure effects on parenting are achieved using the new delivery platform. If Essentials for Parenting Toddlers and Preschoolers is successful at increasing positive parenting and safe, stable, nurturing relationships and environments for children, then CDC has a resource that can be easily and freely disseminated to communities. Ultimately, the results of the work will be disseminated to researchers, states, and the public.

There are no costs to the respondents other than their time. The total estimated annual burden hours is 1,950.

### ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (in hrs)</th>
<th>Total burden (in hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parents (both Natural Navigation [NN] and Guided Navigation [GN] groups)</td>
<td>Screening and Demographics Questionnaires</td>
<td>200</td>
<td>1</td>
<td>15/60</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Detailed Assessment Measures</td>
<td>200</td>
<td>2</td>
<td>45/60</td>
<td>300</td>
</tr>
<tr>
<td></td>
<td>Core Assessment Measures (Rotating)</td>
<td>200</td>
<td>16</td>
<td>15/60</td>
<td>800</td>
</tr>
<tr>
<td></td>
<td>Parental EFP Skills Knowledge Scale</td>
<td>200</td>
<td>10</td>
<td>15/60</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>Parental EFP Skills Usefulness Scale</td>
<td>200</td>
<td>5</td>
<td>15/60</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Therapy Attitude Inventory and System Usability Scale</td>
<td>200</td>
<td>1</td>
<td>15/60</td>
<td>50</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,950</td>
</tr>
</tbody>
</table>

### SUMMARY:


Public comment period: Electronic or written comments must be received March 24, 2015.

### ADDRESSES:

You may submit comments, identified by CDC–2015–0003 and Docket Number NIOSH–279, by either of the following two methods:

- Federal eRulemaking Portal: http://www.regulations.gov Follow the instructions for submitting comments.

Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2015–0003; NIOSH–279]. All relevant comments received will be posted without change http://www.regulations.gov, including any personal information provided. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226.

### SUPPLEMENTARY INFORMATION:

Background: The NIOSH Current Intelligence Bulletin: Reproductive Risks Associated with Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures reviews and summarizes all published studies on adverse reproductive effects of occupational exposures to antineoplastic drugs. Hazardous drugs, especially antineoplastic drugs, are some of the most potent teratogenic chemicals known. In addition, they can affect germinal cells, reproduction, and exposures can result in spontaneous abortion. This document summarizes results of animal studies, occupational epidemiology studies, as well as adverse effects that have been observed in patients treated with these drugs. While workplaces should be safe for all employees, the unique sensitivity of the developing fetus and the infant who is...
breastfeeding necessitate the need for extra precautions when these drugs are handled by both males and females who are trying to conceive, women who may become or who are pregnant, and women who are breast feeding. Recommendations for temporary reassignment of duties or alternative duty are included in this guidance document.

**Information Needs:** Additional data and information are needed to assist NIOSH to protect the reproductive health of healthcare workers who come in contact with antineoplastic drugs. Information is needed for: (1) Appropriateness of guidance, (2) Effect on work practices, (3) Confidentiality issues, (4) Financial impact.

NIOSH seeks to obtain materials, including published and unpublished reports and research findings, to evaluate:

- Relevant publications not included in this document
- Institutional and organizational policies in effect
- Other relevant information related to this topic

**References**


**FOR FURTHER INFORMATION CONTACT:**

Thomas H. Connor, NIOSH, Division of Applied Research and Technologies, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C23, Cincinnati, Ohio 45226–1900. Telephone: (513) 533–8399, Email: hazardousdrugs@cdc.gov.


John Howard,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2015–01209 Filed 1–22–15; 8:45 am]